← Eichor
Study identifier: NCT06822790 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Condition: Hypertriglyceridemia  ·  Sponsor: Arrowhead Pharmaceuticals

PhasePhase 3
Planned participants869
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133). Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of \<=10% within 30 days prior to Day 1. Subjects entering this OLE from AROAPOC3-2003 must meet the following additional criteria to be considered for enrollment in addition to applicable eligibility criteria: 1. HbA1c ≤10% within 30 days prior to Day 1 2. Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND fulfill either (c) or (d) 3. Baseline fasting TG level of ≥500 mg/dL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001 4. Baseline fasting TG level of ≥1000 mg/dL at the time of enrollment into AROAPOC3-2001 All eligible participants will receive plozasiran administered subcutaneously (SC) approxima…

This description comes directly from the study's public registry record.

Talk to the study team

Medical Monitor  ·  626-304-3400  ·  plozasiran@arrowheadpharma.com

Always discuss trial participation with your own doctor first.

Locations (294)

Research Site 21Bakersfield, California, United StatesRecruiting
Research Site 9Beverly Hills, California, United StatesRecruiting
Research Site 11Canoga Park, California, United StatesRecruiting
Research Site 40Garden Grove, California, United StatesRecruiting
Research Site 235Huntington Beach, California, United StatesRecruiting
Research Site 236Lake Forest, California, United StatesRecruiting
Research Site 39Lincoln, California, United StatesRecruiting
Research Site 34Oxnard, California, United StatesRecruiting
Research Site 229Palm Springs, California, United StatesRecruiting
Research Site 275Redding, California, United StatesRecruiting
Research Site 155Fort Lauderdale, Florida, United StatesRecruiting
Research Site 14Hialeah, Florida, United StatesRecruiting

+ 282 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06822790